Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
FDA gives nod to Novartis cancer biosimilar
Americas
The US Food and Drug Administration has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.   5 January 2015
Ibuprofen agreement signed with mystery healthcare company
Americas
US pharmaceutical company Strategic Science and Technologies has signed an option agreement with “one of the world’s largest over-the-counter healthcare companies” to commercialise one of its ibuprofen products.   22 December 2014
Americas
Law firm Fitzpatrick, Cella, Harper, & Scinto will begin the New Year with three new faces in its partnership.   19 December 2014
Americas
A US biotechnology company that was on the winning side of an EU court ruling surrounding the patentability of certain organisms has said it “clears the way” for patents in Europe.   19 December 2014
article
The battle between innovative pharma companies and generic drug rivals is a constant source of interest.   19 December 2014
Big Pharma
France-based pharmaceutical company Flamel Technologies has moved its IP to Ireland.   18 December 2014
Europe
Europe’s highest court has said that an organism incapable of developing into a human does not constitute a human embryo and therefore uses of it can be patented.   18 December 2014
Americas
The US Patent and Trademark Office has issued new guidance for determining what claims are eligible for patenting, with one lawyer saying it could “muddy the waters”.   17 December 2014
Asia
Bayer has lost an attempt to block a generic version of its cancer drug Nexavar (Sorafenib) in India after the country’s highest court rejected an appeal from the German pharmaceutical company.   16 December 2014
Big Pharma
Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.   12 December 2014